BACKGROUND: High-volume haemofiltration (HVHF) has been suggested as an adjuvant treatment of septic shock due to its capacities to remove from blood both pro- and anti-inflammatory mediators involved in the sepsis syndrome. Adsorption properties of some haemofiltration membranes are also interesting with this indication because inflammatory mediators are caught in the membrane itself. The aim of this study was to determine the haemodynamic and immunological effects of a new haemofiltration membrane, which has enhanced adsorption properties due to a special surface treatment, allowing the adsorption of endotoxins. METHODS: We compared this membrane to a standard haemofiltration membrane both in vitro and in 20 sepsis-induced pigs, randomized in two groups. One group was haemofiltered with the treated membrane and the other with the standard haemofiltration membrane during 6-h HVHF sessions. RESULTS: At the end of the experiment, mean +/- SD crystalloids requirements (5937 +/- 1588 versus 7587 +/- 1456 ml, P = 0.026), colloids requirements (1437 +/- 320 versus 1912 +/- 538 ml, P = 0.027), lactic acidosis (pH = 7.20 +/- 0.11 versus 7.10 +/- 0.07, P = 0.026) and pulmonary arterial hypertension (MPAP = 24 +/- 7 versus 34 +/- 8 mmHg, P = 0.008) were less pronounced when HVHF was performed with the treated membrane. In addition, mean +/- SD endotoxins levels were lower in the treated membrane group after 1 hour of HVHF (1.91 +/- 1.19 versus 11.07 +/- 10.64 EU/ml, P = 0.035). Cytokines levels were not different between groups except for IL-1beta, which was slightly lower in the treated membrane group. CONCLUSIONS: The use of a membrane with enhanced adsorption properties during a 6-h HVHF session in septic pigs improves haemodynamics compared to a standard haemofiltration membrane. These results are probably due to an efficient endotoxins and cytokines adsorption. A human study using this membrane is now necessary to confirm these results.
BACKGROUND: High-volume haemofiltration (HVHF) has been suggested as an adjuvant treatment of septic shock due to its capacities to remove from blood both pro- and anti-inflammatory mediators involved in the sepsis syndrome. Adsorption properties of some haemofiltration membranes are also interesting with this indication because inflammatory mediators are caught in the membrane itself. The aim of this study was to determine the haemodynamic and immunological effects of a new haemofiltration membrane, which has enhanced adsorption properties due to a special surface treatment, allowing the adsorption of endotoxins. METHODS: We compared this membrane to a standard haemofiltration membrane both in vitro and in 20 sepsis-induced pigs, randomized in two groups. One group was haemofiltered with the treated membrane and the other with the standard haemofiltration membrane during 6-h HVHF sessions. RESULTS: At the end of the experiment, mean +/- SD crystalloids requirements (5937 +/- 1588 versus 7587 +/- 1456 ml, P = 0.026), colloids requirements (1437 +/- 320 versus 1912 +/- 538 ml, P = 0.027), lactic acidosis (pH = 7.20 +/- 0.11 versus 7.10 +/- 0.07, P = 0.026) and pulmonary arterial hypertension (MPAP = 24 +/- 7 versus 34 +/- 8 mmHg, P = 0.008) were less pronounced when HVHF was performed with the treated membrane. In addition, mean +/- SD endotoxins levels were lower in the treated membrane group after 1 hour of HVHF (1.91 +/- 1.19 versus 11.07 +/- 10.64 EU/ml, P = 0.035). Cytokines levels were not different between groups except for IL-1beta, which was slightly lower in the treated membrane group. CONCLUSIONS: The use of a membrane with enhanced adsorption properties during a 6-h HVHF session in septic pigs improves haemodynamics compared to a standard haemofiltration membrane. These results are probably due to an efficient endotoxins and cytokines adsorption. A human study using this membrane is now necessary to confirm these results.
Authors: Zhi-Yong Peng; Jicheng Zhang; Thomas Rimmelé; Feihu Zhou; Anan Chuasuwan; A Murat Kaynar; John A Kellum Journal: J Surg Res Date: 2013-08-06 Impact factor: 2.192
Authors: Olivier Joannes-Boyau; Patrick M Honoré; Paul Perez; Sean M Bagshaw; Hubert Grand; Jean-Luc Canivet; Antoine Dewitte; Claire Flamens; Wilfried Pujol; Anne-Sophie Grandoulier; Catherine Fleureau; Rita Jacobs; Christophe Broux; Hervé Floch; Olivier Branchard; Stephane Franck; Hadrien Rozé; Vincent Collin; Willem Boer; Joachim Calderon; Bernard Gauche; Herbert D Spapen; Gérard Janvier; Alexandre Ouattara Journal: Intensive Care Med Date: 2013-06-06 Impact factor: 17.440
Authors: Jens Altrichter; Martin Sauer; Katharina Kaftan; Thomas Birken; Doris Gloger; Martin Gloger; Jörg Henschel; Heiko Hickstein; Ernst Klar; Sebastian Koball; Annette Pertschy; Gabriele Nöldge-Schomburg; Dierk A Vagts; Steffen R Mitzner Journal: Crit Care Date: 2011-03-03 Impact factor: 9.097
Authors: Karla C L Lee; Luisa A Baker; Giacomo Stanzani; Hatim Alibhai; Yu Mei Chang; Carolina Jimenez Palacios; Pamela J Leckie; Paola Giordano; Simon L Priestnall; Daniel J Antoine; Rosalind E Jenkins; Christopher E Goldring; B Kevin Park; Fausto Andreola; Banwari Agarwal; Rajeshwar P Mookerjee; Nathan A Davies; Rajiv Jalan Journal: J Hepatol Date: 2015-05-01 Impact factor: 25.083
Authors: Thomas Rimmelé; Ata Murat Kaynar; Joseph N McLaughlin; Jeffery V Bishop; Morgan V Fedorchak; Anan Chuasuwan; Zhiyong Peng; Kai Singbartl; Daniel R Frederick; Lin Zhu; Melinda Carter; William J Federspiel; Adriana Zeevi; John A Kellum Journal: Crit Care Date: 2013-03-26 Impact factor: 9.097